Nicotine and Its Potential Role in Treating COVID-19 and Long COVID

‍

Nicotine, known mainly as an addictive substance, is gaining interest as a possible treatment for COVID-19 and long COVID. While associated with smoking, nicotine—particularly in patch form—may offer benefits for symptom management through its influence on neurotransmitter release, immune modulation, and autonomic nervous system function. Here’s a deeper look at nicotine’s potential role in managing these complex conditions.

1. Nicotine and the Cholinergic System: A Balancing Act

Nicotine may help in these conditions by acting on the cholinergic system, which includes acetylcholine, a neurotransmitter regulating both nervous and immune functions. This system significantly influences the parasympathetic nervous system (PNS), which governs “rest and digest” responses and immune balance. Nicotine’s effect on the cholinergic anti-inflammatory pathway could benefit people with long COVID, where an overactive immune response is often an issue. Studies suggest that COVID-19 may disrupt nicotinic acetylcholine receptors (nAChRs), impairing normal autonomic balance.

Researchers like Dr. Marco Leitzke hypothesize that nicotine may help by competing with viral interference at these receptors, thereby allowing the nervous and immune systems to regain a more balanced function. Preliminary findings indicate that low-dose nicotine patches may alleviate symptoms related to autonomic instability, such as fatigue and cognitive issues, in patients with long COVID.

2. Brain Fog, Cognitive Effects, and Nicotine Withdrawal

Nicotine may also help with “brain fog,” a common complaint among long COVID patients, by enhancing levels of neurotransmitters like dopamine and serotonin. These neurotransmitters are involved in memory, attention, and cognitive function, areas often impaired in long COVID. A meta-analysis found nicotine to be effective in improving focus, memory, and attention, suggesting it could aid those struggling with post-COVID cognitive challenges. Importantly, slow-release delivery via patches minimizes the addiction risks associated with rapid nicotine delivery methods like smoking.

However, quitting nicotine can lead to withdrawal symptoms, including brain fog and difficulty concentrating, as the body adjusts to the absence of nicotine’s stimulating effects. Patient reports indicate that nicotine patches can help reduce brain fog for some individuals with long COVID, though responses vary widely, underscoring the need for a personalized approach.

3. Nicotine’s Impact on Exercise Tolerance and Cardiovascular Effects

Long COVID frequently affects cardiovascular health, leading to symptoms such as exercise intolerance and chronotropic incompetence, where the heart does not adequately increase its rate during activity. Nicotine’s mild stimulant effect may help increase heart rate and improve blood flow, potentially enhancing exercise tolerance. However, this requires caution, especially in individuals with pre-existing cardiovascular conditions, as nicotine can temporarily raise blood pressure and heart rate. Patients using nicotine patches are generally advised to start with low doses to assess tolerance and monitor side effects.

4. The 2023 Leitzke Study and Patient Experiences with Nicotine Patches

Dr. Leitzke’s 2023 study reported that four patients using 7.5 mg nicotine patches experienced improvements in cognitive function and fatigue after several days of use. Some patients noted sustained relief for several months. Leitzke recommends starting with a low dose, such as a 7 mg patch, as nicotine can initially cause side effects like nausea or dizziness, which typically subside as the body adjusts.

Online patient feedback suggests nicotine patches may provide significant relief for some, though not all, patients. Approximately 20% of patients report substantial improvement in symptoms like brain fog and fatigue, with 36% experiencing moderate relief. However, others report little to no benefit, highlighting the importance of tailoring nicotine use to individual responses.

5. Risks and Cautions

Nicotine patches provide a controlled, slow-release dose that helps mitigate the risks of addiction seen in smoking. However, caution is essential, as improper use or overuse can lead to dependency and cardiovascular side effects. Although patches help avoid the rapid dopamine spikes associated with smoking, they should be used as directed to minimize the risks of misuse.

Additionally, some studies suggest that nicotine could affect ACE2 receptor expression, which SARS-CoV-2 uses to enter cells. Evidence is mixed, with findings suggesting nicotine may either increase ACE2 expression in certain tissues or decrease it in others. This adds complexity to nicotine’s role in managing COVID-19, emphasizing the importance of using nicotine patches under healthcare guidance.

FAQ Section

Can you cut nicotine patches in half?
No, cutting nicotine patches is generally not recommended, as this can interfere with their controlled-release mechanism and lead to an uneven release of nicotine. Always follow dosage instructions on the packaging or consult a healthcare provider if you need to adjust your dosage.

Does nicotine cause brain fog?
Nicotine can both relieve and contribute to brain fog. While nicotine’s effects on dopamine and serotonin may enhance focus, cognitive issues can arise when quitting, as withdrawal impacts concentration and cognitive clarity. Slow-release patches may help manage these effects without the cognitive fluctuations seen with smoking.

Why does nicotine make me tired?
For some, nicotine has a paradoxical effect and may cause fatigue or drowsiness, particularly if used at higher doses or if one is sensitive to its effects. Starting with a low-dose patch can help determine how nicotine affects you personally.

References

• "The Role of Nicotine in COVID-19 Infection." Centre for Evidence-Based Medicine, University of Oxford, www.cebm.net/covid-19/nicotine-in-covid-19. Accessed 26 Oct. 2024.
• Cort, Johnson. "The Nicotine Patch: Long COVID, ME/CFS and Fibromyalgia." Health Rising, 19 Sept. 2023, www.healthrising.org/blog/2023/09/19/nicotine-patch-long-covid-fibromyalgia-mecfs.
• “NIH Opens Long COVID Trials to Evaluate Treatments for Autonomic Nervous System Dysfunction.” National Institutes of Health, 12 Mar. 2024, www.nih.gov/news-events/news-releases/nih-opens-long-covid-trials-evaluate-treatments-autonomic-nervous-system-dysfunction.
• Backman, Isabella. "New Evidence Supports Autoimmunity as One of Long COVID’s Underlying Drivers." Yale School of Medicine, 22 July 2024, medicine.yale.edu/news-article/new-evidence-supports-autoimmunity-as-one-of-long-covids-underlying-drivers.
• Desai, Hiren, et al. "Post-COVID Postural Orthostatic Tachycardia Syndrome (POTS): A New Phenomenon." Frontiers in Neurology, vol. 12, 2022, www.frontiersin.org/articles/10.3389/fneur.2022.810354/full.
• Leitzke, Marco. Is the Post-COVID-19 Syndrome a Severe Impairment of Acetylcholine-Orchestrated Neuromodulation that Responds to Nicotine Administration?

‍